Clinical evaluation of ALS drugs

Neurology

Volumn 48, Issue 4 SUPPL. 4, 1997, Pages

  Brooks, Benjamin Rix ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; BRAIN DERIVED NEUROTROPHIC FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTAMIC ACID; NEUROTROPIC AGENT; PROTEASE NEXIN I; PROTEINASE INHIBITOR; RILUZOLE; SOMATOMEDIN C;

AMYOTROPHIC LATERAL SCLEROSIS; AUTOIMMUNITY; CONFERENCE PAPER; DEGENERATIVE DISEASE; ELECTROMYOGRAPHY; LUNG FUNCTION TEST; NERVE DEGENERATION; NEUROLOGIC EXAMINATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PYRAMIDAL TRACT; QUALITY OF LIFE;

EID: 0030898561     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.48.4_suppl_4.23s     Document Type: Conference Paper

References (24)

1. Munsat TL. Development of measurement techniques. Neurology 1996;47(suppl 2):S83-S85.
2. Rothstein JD. Excitotoxicity hypothesis. Neurology 1996; 47(suppl 2):S19-S26.
3. Siddique T, Nijhawan D, Hentati A. Molecular genetic basis of familial ALS. Neurology 1996;47(suppl 2):S27-S35.
4. Pall HS. Motor neurone disease. Rev Clin Gerontol 1995;5: 303-311.
5. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613-622.
6. Brooke MH, Strong MJ. Advances in ALS Workshop Summary: research and future goals. Neurology 1996;47(suppl 2): S108-S112.
7. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357-366.
8. Bensimon G, Lacomblez L, Meininger V, and the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
9. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, for the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
10. Miller RG, Moore D, Young LA, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996;47:1383-1388.
11. Festoff BW. Amyotrophic lateral sclerosis: current and future treatment strategies. Drugs 1996;51:28-44.
12. Mitsumoto H, Olney RK. Drug combination treatment in patients with ALS: current status and future directions. Neurology 1996;47(suppl 2):S103-S107.
13. Bromberg MB, Brooks BR. Issues in clinical trial design II: selection of end point measures. Neurology 1996;47(suppl 2): S100-S102.
14. World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Diseases. Airlie House Guidelines: therapeutic trials in amyotrophic lateral sclerosis. J Neurol Sci 1995;129(suppl):1-10.
15. World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Amyotrophic Lateral Sclerosis. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994; 124(Suppl):96-107.
16. Brooks BF, Sufit RL, DePaul R, De Tan Y, Sanjak M, Robbins J. Design of clinical therapeutic trials in amyotrophic lateral sclerosis. Adv Neurol 1991;56:521-546.
17. Louwerse ES, Bossuyt PMM, Weverling GJ, Vianney de Jong JMB. Mortality risk stratification in amyotrophic lateral sclerosis. J Neurol Sci 1995;129(suppl):27.
18. Brooks BR, Shodis KA, Lewis DH, et al. Natural history of amyotrophic lateral sclerosis. Quantification of symptoms, signs, strength, and function. In: Serratrice G, Munsat T, eds. Pathogenesis and therapy of amyotrophic lateral sclerosis. Advances in neurology. Philadelphia: Lippincott-Raven, 1995: 163-184.
19. Munsat TL, Hollander D, Andres P, Finison L. Clinical trials in ALS: measurement and natural history. Adv Neurol 1991; 56:515-519.
20. Brooks BR. Natural history of ALS: symptoms, strength, pulmonary function, and disability. Neurology 1996;47(suppl 2): S71-S82.
21. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987;22:328-333.
22. Lange DJ, Felice KJ, Festoff BW, et al. Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. Neurology 1996;47(suppl 2): S93-S95.
23. Andres PL, Hedlund W, Finison L, Conlon T, Felmus M, Munsat TL. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 1986;36:937-941.
24. ALS CNTF Treatment Study (A.C.T.S.) Phase I-II Study Group. The ALS Functional Rating scale: assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 1994;53:141-147.